Back to Search Start Over

Nobody dares stopping clinical research, not even COVID-19

Nobody dares stopping clinical research, not even COVID-19

Authors :
Andrea Malfettone
Serena Di Cosimo
José Manuel Pérez-García
Alicia García
Miguel Sampayo-Cordero
Leonardo Mina
Carolina Herrero
Antonio Llombart-Cussac
Javier Cortés
Source :
npj Breast Cancer, Vol 7, Iss 1, Pp 1-3 (2021)
Publication Year :
2021
Publisher :
Nature Portfolio, 2021.

Abstract

In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insights. Though limited by sample size, our data emphasize the importance of quickly adopting measures that first prioritize patient safety and data validity, then consider contingency measures such as telemedicine, virtual medical review, and remote monitoring. Successful adaptations of healthcare and patient management in response to COVID-19 have been fundamental to ensuring continuing clinical cancer research.

Details

Language :
English
ISSN :
23744677
Volume :
7
Issue :
1
Database :
Directory of Open Access Journals
Journal :
npj Breast Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.33b48eb9a9dd438c9f6dd121fdf66906
Document Type :
article
Full Text :
https://doi.org/10.1038/s41523-021-00249-1